- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Nov 2025 | 3 Nov 2025 |
| Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2025 Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2025. (As Per BSE Announcement Dated on 14.11.2025) | ||
| Board Meeting | 26 Sep 2025 | 22 Sep 2025 |
| Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/09/2025 inter alia to consider and approve payment of interim dividend if any on Equity Shares of the Company for the financial year 2025-26. Outcome Of The Board Meeting Held On 26Th September, 2025 The Board approved Interim Dividend of Rs. 2.50 per equity shares on face value of Re. 1/- per equity shares for the Financial Year 2025-26 and reconstitution of Committees. (As Per BSE Announcement Dated on 26.09.2025) | ||
| Board Meeting | 14 Aug 2025 | 4 Aug 2025 |
| Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30 2025. Please find attached herewith Unaudited Financial Results for the first quarter ended 30th June, 2025 (As Per BSE Announcement Dated on: 14.08.2025) | ||
| Board Meeting | 23 May 2025 | 12 May 2025 |
| Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31 2025 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2025. The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on 23rd May, 2025, which commenced at 02.00 p.m. and concluded at 04:54 p.m., considered and approved the following: 1. Audited Financial Results for the quarter and year ended March 31, 2025. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com. 2. Recommended Dividend @ 250% i.e. Rs. 2.5/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2024-25 subject to the approval of the Shareholders at the ensuing Annual General Meeting. (As Per BSE Announcement Dated on: 23/05/2025) | ||
| Board Meeting | 14 Feb 2025 | 3 Feb 2025 |
| GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31 2024. Outcome of the Board Meeting dated 14th February, 2025. (As Per Bse Announcement Dated on 14.02.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.